{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Disease&page=17", "query": { "condition": "Non-Hodgkin's Disease", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 2117, "total_pages": 212, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Disease&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Disease&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T02:18:23.038Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00520130", "title": "Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Hodgkin's Lymphoma", "Non-Hodgkin's Disease", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Allogenic stem cell transplant (ASCT)", "type": "DRUG" }, { "name": "Conditioning Chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 92, "start_date": "2007-10-30", "completion_date": "2018-12-31", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520130" }, { "nct_id": "NCT01657331", "title": "Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Neulasta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2012-07", "completion_date": "2018-06", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01657331" }, { "nct_id": "NCT05107856", "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "B-cell Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myelomonocytic Leukemia", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndromes", "Myeloproliferative Neoplasm", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "PRT1419", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2022-03-22", "completion_date": "2024-01-19", "has_results": false, "last_update_posted_date": "2024-01-31", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 9, "location_summary": "Orange City, Florida • Orlando, Florida • Bethesda, Maryland + 6 more", "locations": [ { "city": "Orange City", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Brick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107856" }, { "nct_id": "NCT02763254", "title": "Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Lymphoma, Large B-Cell, Diffuse", "Post-transplant Lymphoproliferative Disorder" ], "interventions": [ { "name": "baltaleucel-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cell Medica Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1, "start_date": "2016-11", "completion_date": "2018-02-17", "has_results": true, "last_update_posted_date": "2019-03-26", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02763254" }, { "nct_id": "NCT01992653", "title": "A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non Hodgkin" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2013-11-29", "completion_date": "2018-12-19", "has_results": true, "last_update_posted_date": "2023-03-14", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Greeley, Colorado • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Greeley", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01992653" }, { "nct_id": "NCT04986865", "title": "A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Mature B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "ATG-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Antengene Biologics Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2021-12-15", "completion_date": "2025-01-31", "has_results": false, "last_update_posted_date": "2025-06-09", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 3, "location_summary": "San Francisco, California • St Louis, Missouri • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04986865" }, { "nct_id": "NCT01767766", "title": "Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Peripheral T-Cell Lymphoma", "Hodgkin's Lymphoma" ], "interventions": [ { "name": "TGR-1202", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2013-01-07", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2021-08-23", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 7, "location_summary": "Sarasota, Florida • Hackensack, New Jersey • New York, New York + 4 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01767766" }, { "nct_id": "NCT00217412", "title": "Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Acute Promyelocytic Leukemia (M3)", "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Juvenile Myelomonocytic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Neuroblastoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 60, "start_date": "2005-08", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2014-06-17", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217412" }, { "nct_id": "NCT01699581", "title": "Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin's Lymphoma", "Multiple Myeloma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Nestle Impact Advanced Recovery", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Greg Monohan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2012-09", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2016-10-18", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01699581" }, { "nct_id": "NCT02343666", "title": "HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus 1 Positive", "Stage I Adult Hodgkin Lymphoma", "Stage I Adult Non-Hodgkin Lymphoma", "Stage II Adult Hodgkin Lymphoma", "Stage II Adult Non-Hodgkin Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Non-Hodgkin Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs", "type": "BIOLOGICAL" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "O6-Benzylguanine", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 0, "start_date": "2016-08-15", "completion_date": null, "has_results": false, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-10-14T02:18:23.038Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02343666" } ] }